AbbVie is spearheading a new battle in pharma’s long-running fight to reform the federal government’s 340B drug discount program with a lawsuit that challenges the definition of what it means to be a ...
The 340B Drug Pricing Program was designed to help safety net providers serve low-income patients, but it has since ballooned into a multibillion-dollar system dominated by large health systems — with ...
On March 17, 2026, the Ninth Circuit issued a unanimous decision in United States ex rel. Adventist Health Sys. of W. v. AbbVie Inc. allowing a large health system to pursue a False Claims Act (FCA) ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果